| Entries |
| Document | Title | Date |
|---|
| 20100273708 | ADIPONECTIN EXPRESSION-INDUCING AGENTS AND USES THEREOF - The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position −188 to position −157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases. | 10-28-2010 |
| 20100286044 | DETECTION OF TISSUE ORIGIN OF CANCER - Disclosed is a method for determining the cellular or tissue origin of tumor cells. The method entails determining the presence of at least one micro RNA (miRNA) in a sample derived from tumor tissue and based on the said determination establishing a miRNA expression profile and comparing this with pre-established miRNA expression profiles from cells, tissues or tumors. The determination uses short oligonucleotide probes comprising modified affinity-enhancing nucleobases. | 11-11-2010 |
| 20100292147 | IDENTIFICATION OF THE HEPCIDIN BINDING SITE ON FERROPORTIN - The invention relates to materials and procedures for the use of the hepcidin binding domain (HBD) on ferroportin. A 20 amino acid peptide of the HBD was synthesized and shown to recapitulate the characteristics and specificity of hepcidin binding to cell surface ferroportin. The affinity of hepcidin for the HBD peptide permits a rapid, sensitive assay of hepcidin in biological fluids. | 11-18-2010 |
| 20110039775 | THYROID STIMULATING HORMONE FUSION PROTEINS - We disclose TSH fusion proteins comprising TSHα and/or TSH β and methods to treat diseases that would benefit from administration of TSH agonists and antagonists. | 02-17-2011 |
| 20110046058 | COMPOSITIONS FOR ENTERAL ABSORPTION AND SUSTAINED ACTION OF LEPTIN-RELATED PEPTIDES USEFUL IN THE TREATMENT OF OBESITY AND LEPTIN-MODULATED DISEASE - The invention relates generally to enterally absorbed peptide compositions and more specifically to leptin-related peptide compositions, methods of administration, and methods of modulating the speed and sustained action of systemic absorption of such peptides useful in the treatment of obesity and other leptin modulated diseases. | 02-24-2011 |
| 20110053844 | LIQUID FORMULATION OF G-CSF CONJUGATE - The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer, the composition having a pH value in the range of 4.5 to 5.5. The composition further comprises a surfactant and optionally one or more other pharmaceutically acceptable excipients. Further, the composition of the invention is free from tartaric acid or salts thereof and from succinic acid and salts thereof as buffering agents and does not contain amino acids as stabilizer. The composition has a good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies. | 03-03-2011 |
| 20110053845 | LOCALIZED VAGINAL DELIVERY WITHOUT DETRIMENTAL BLOOD LEVELS - The invention relates to a pharmaceutical composition for vaginal administration of a treating agent normally associated with undesired side effects at detrimental blood levels. The composition releases the treating agent at a rate to achieve local tissue concentrations without such detrimental blood levels by using a therapeutically effective amount of the treating agent and a bioadhesive, cross-linked water swellable, but water-insoluble polycarboxylic acid polymer. Using this composition and the method of treatment provides sufficient local levels of the drug to provide therapeutic efficacy, but avoids many untoward adverse events. The invention also relates to a pharmaceutical composition for use during menses that includes a treating agent and a bioadhesive, cross-linked water swellable, but water-insoluble polycarboxylic acid polymer. | 03-03-2011 |
| 20110065638 | NOVEL CRUSTACEAN ANDROGENIC GLAND HORMONE - The present invention relates to a novel crustacean androgenic gland hormone. More specifically, the invention relates to an androgenic gland hormone derived from | 03-17-2011 |
| 20110086799 | GnRH II Analogs and Uses Thereof in the Immune System - Specially designed GnRH II analogs that are resistant to degradation by peptidases, are disclosed. The GnRH II analogs incorporate D-Arg, D-Leu, D-tBu-Ser, D-Trp, D-Asn or other active D amino acids at position 6 and aza-Gly-amide or other amino acid-amide at position 10. The D-Arg (6)—GnRH II-aza-Gly (10)-amide, D-Asn—GnRH II-aza-Gly (10)-amide, and D-Leu(6)—GnRH II-aza-Gly(10)-amide analogs are also provided, and demonstrate preferential binding to immune system GnRH receptors. These GnRH II analogs or their antibodies may be used in pharmaceutical preparations, and specifically in treatment of various immune system disorders. Antibodies to GnRH II, Applicant's GnRH TI analogs, and GnRH receptors can be used for the detection of GnRH II or the GnRH II analog or the GnRH II receptors as a diagnostic tool and/or to monitor treatment. | 04-14-2011 |
| 20110086800 | SCREENING METHOD FOR PREDICTING SUSCEPTIBILITY TO BREAST CANCER - A method to aid in identifying a familial or sporadic pattern of risk in at least one individual for developing cancer of a mucosal epithelial tissue, the method comprising screening said at least one individual for heterozygosity or homozygosity for a mutation in a gene coding for a Poly-Ig (Fc) receptor or a Poly-Ig-like (Fc) receptor capable of mediating inhibition of cancer cell growth by an immunoglobulin inhibitor. A method of treating an individual so identified includes enhancing the amount of immunoglobulin inhibitor contacting a mucosal epithelial tissue of said individual, and, especially in individuals homozygous for the defective receptor, may also include prophylactic surgery. Other methods include implementation of a risk reduction or prevention program in individuals identified as being at risk. | 04-14-2011 |
| 20110092423 | INHIBITORS OF Akt ACTIVITY - Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 04-21-2011 |
| 20110098221 | INHIBITORS OF Akt ACTIVITY - Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 04-28-2011 |
| 20110105397 | METHOD FOR TREATING HEART FAILURE WITH STRESSCOPIN-LIKE PEPTIDES - The present invention relates to novel methods of treating heart failure comprising administering an amount of stresscopin-like peptide to a subject in need thereof; and substantially maintaining the amount of said peptide present in the plasma of said subject at a concentration resulting in a therapeutic benefit without a substantial increase in the heart rate of said subject. The method involves the use of stresscopin-like peptides that are selective corticotrophin releasing hormone receptor type 2 (CRHR2) agonists. | 05-05-2011 |
| 20110124562 | APOAEQUORIN-CONTAINING COMPOSITIONS AND METHODS OF USING SAME - Compositions containing apoaequorin and methods for their use in treating symptoms and disorders related to calcium imbalances associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided by the present invention. | 05-26-2011 |
| 20110144016 | Methods and Compositions for Treating Cancer - Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C | 06-16-2011 |
| 20110160133 | METHOD FOR INHIBITING INFLAMMATION AND PRE-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE - The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin. | 06-30-2011 |
| 20110160134 | Device and Method for Making Solid Beads - A method of making solid beads is disclosed, said method comprising: (i) providing a microfluidic device comprising a carrier fluid conduit and a functional fluid conduit which meet at a junction region; (ii) providing a laminar flow of a functional fluid comprising a solvent and a solute along the functional fluid conduit and providing a laminar flow of a carrier fluid along the carrier fluid conduit so as to form droplets of functional fluid in a flow of carrier fluid; (iii) cooling the segments of functional fluid in a conduit of the microfluidic device to form cooled (preferably frozen) droplets; and (iv) providing a liquid into intimate admixture with the cooled droplets so as to cause said solvent to exit said cooled droplets, thus forming solid beads. A microfluidic device for use in such a method is also disclosed. | 06-30-2011 |
| 20110166069 | COMPOSITIONS AND METHODS FOR STIMULATING GASTROINTESTINAL MOTILITY - The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient. | 07-07-2011 |
| 20110172151 | DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS, AND METHODS OF USE THEREOF - The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention. | 07-14-2011 |
| 20110195898 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS - Methods of treating, mitigating, slowing the progression of, or preventing Alzheimer's Disease and Mild Cognitive Impairment (MCI) include administration of gonadotropin-releasing hormone analogs in combination with acetylcholinesterase inhibitors and/or N-methyl-D-aspartate receptor antagonists. | 08-11-2011 |
| 20110201553 | Systemic Pro-hemostatic Effect of Sympathicomimetics with Agonistic Effects on Alfa-Adrenergic and/or Beta-Adrenergic Receptors of the Sympathetic Nervous System, Related to Improved Clot Strength - The present invention relates to a novel use and methods of treatment using sympathicomimetic agonists with pro-hemostatic activity. | 08-18-2011 |
| 20110218146 | ADIPONECTIN FOR TREATING PULMONARY DISEASE - The present invention provides an agent for inhibiting alveolar airspace enlargement containing adiponectin or an agent for inhibiting alveolar wall destruction containing adiponectin. The pulmonary disease therapeutic agents of the present invention are highly safe drugs that possess an excellent effect of decreasing the deterioration of the pulmonary function, such as airflow limitation, and exhibit an extremely high effect of treating pulmonary disease accompanied by irreversible deterioration in pulmonary function, with fewer adverse side effects such as nausea, vomiting and gastric acid secretion. | 09-08-2011 |
| 20110224140 | HUMAN CHORIONIC GONADOTROPIN (HCG) ORALLY OR FOR INJECTION FOR THE TREATMENT OF MOOD DISORDERS AND ALCOHOLISM - An HCG preparation for oral administration or for injection used either as a simple dilution or coupled to albumin or a cyclodextrin therapeutically effective in the treatment of mood disorders including (but not limited to) neurosis, irritability, depressive states and borderline states. HCG preparation as above described is also effective in the treatment of all types of alcoholism. | 09-15-2011 |
| 20110301087 | CRF1 RECEPTOR COMPOUNDS - The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor for corticotrophin releasing hormone (or factor) receptor 1, also known as the CRF1, CRHR1, CRFR1, CRHR, CRF-R. The CRF1 receptor compounds are derived from the intracellular loops and domains of CRF1 receptor. The invention also relates to the use of these CRF1 receptor compounds and pharmaceutical compositions comprising the CRF1 receptor compounds in the treatment of diseases and conditions associated with CRF1 receptor modulation, such as inflammatory bowel disease (peripherally acting), irritable bowel syndrome (IBS), stress response (colonic motor activity), anxiety, sleep disorder, addictive behavior, acute and chronic neurodegeneration, preterm labor and pain. | 12-08-2011 |
| 20110312888 | METHOD OF DETECTING AND/OR MEASURING HEPCIDIN IN A SAMPLE - Methods of isolating and/or analyzing hepcidin by mass spectrometry and methods of quantifying hepcidin are disclosed. | 12-22-2011 |
| 20120028897 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID RETENTION DISORDERS - Methods of treating fluid retention disorders with the B isomers of guanylin family peptides are described herein. UgnB, when compared to the A isomer (UgnA), exhibits a conventional sigmoidal dose-response relationship in its natriuetic activity. Further, unlike UgnA, UgnB only weakly activates the GC-C receptor. Compositions comprising purified, or mixtures containing B isomers of guanylin family peptides are described herein are therefore useful for the treatment of fluid retention disorders. | 02-02-2012 |
| 20120040901 | NOVEL BIOMATERIALS, THEIR PREPARATION AND USE - The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps:
| 02-16-2012 |
| 20120101037 | GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE ANALOGS - The present invention provides compounds which are analogs of glucose-dependent insulinotropic polypeptide (GIP) and pharmaceutically acceptable salts of such compounds. These compounds have activity as agonists of GIP receptor. | 04-26-2012 |
| 20120115781 | Methods For Evaluating and Implementing Prostate Disease Treatments - Provided is a method for evaluating test agents as candidates for treating prostatic diseases, including benign prostatic hyperplasia and androgen dependent and androgen independent prostate cancer. The method comprises providing a mouse comprising a human prostate primary xenograft, where the xenograft contains blood vessels that include human endothelial cells, initiating androgen deprivation in the mouse, administering to the mouse a test agent within a period of 1-7 days after initiating the androgen deprivation, and determining a reduction in human epithelial cells in the xenografts and/or a reduction in number of the endothelial cells or blood vessels in the xenograft. Also provided is a method for treating an individual for human prostate cancer or benign prostatic hyperplasia. The method comprises initiating androgen deprivation in the individual and administering to the individual an agent capable of inducing apoptosis of vascular endothelial cells within a period of 1-7 days of initiating androgen deprivation. | 05-10-2012 |
| 20120115782 | COMPOSITIONS AND METHODS FOR TREATING OR INHIBITING LIVER INJURY - The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. The invention also relates inter alia to methods of inhibiting or reducing the likelihood of liver injury secondary to hepatitis, cirrhosis and a number of other disease states and conditions and further may be used to reduce the likelihood of a patient at risk or treating a patient for inter alia hepatitis, cirrhosis, non-alcoholic fatty liver diseases (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis and other disease states and conditions as otherwise described. Pharmaceutical compositions are also described. | 05-10-2012 |
| 20120122779 | Method for site-specific polyvalent display on polymers - The present invention relates to novel complex peptidomimetic products comprising multiple homogeneous or heterogeneous pendant groups that are site-specifically positioned along a linear oligomer or polymer scaffold and methods of making thereof. More specifically, the invention relates to N-substituted glycine peptoid oligomers or peptoids and their use as substrates for azide-alkyne [3+2]-cycloaddition conjugation reactions and subsequent additional rounds of oligomerization and cycloaddition. The methods of the invention may also be used to generate peptoid-peptide hybrid or peptide products comprising multiple homogeneous or heterogeneous pendant groups, which are positioned precisely along the linear oligomer or polymer scaffold. | 05-17-2012 |
| 20120129773 | METHODS OF TREATING AUTISM AND AUTISM SPECTRUM DISORDERS - The present invention relates to methods of treating a subject diagnosed with autism or an autism spectrum disorder, lowering the level of mercury in a subject determined to contain a high level of mercury, methods of lowering the level of mercury in a child diagnosed with autism, lowering the level of at least one androgen in a subject diagnosed with autism, lowering the level of mercury and the level of at least one androgen in a subject diagnosed with autism and methods of assessing the risk of whether a child is susceptible of developing autism. | 05-24-2012 |
| 20120172301 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANGIOTENSIN-(1-9), DERIVATIVES THEREOF, OR A VECTOR EXPRESSING ACE2, USEFUL FOR TREATING CARDIOVASCULAR, PULMONARY, CEREBRAL, AND/OR RENAL REMODELING - The present invention relates to a pharmaceutical composition comprising an effective amount of angiotensin-(1-9) or derivatives thereof, and at least one pharmaceutical acceptable carrier, excipient, stabilizer, diluent, and/or adjuvant. Additionally, the present invention describes the use of the pharmaceutical composition and the angiotensin-(1-9) peptide or peptides derived thereof which are biological or chemical analogous for the manufacture of medicaments useful for preventing, reverting, inhibiting, and/or reducing cardiovascular, pulmonary, cerebral, or renal remodeling. Additionally, this invention also comprises a method for preventing, reverting, inhibiting, and/or reducing cardiovascular, pulmonary, cerebral, or renal remodeling comprising elevating blood and/or tissue concentration of angiotensin-(1-9) or derivatives thereof peptide via a pharmaceutical composition that contains a vector expressing ACE2, enzyme responsible for the endogenous production of angiotensin-(1-9). These vectors correspond to adenovirus, retrovirus, lentivirus, or adeno-associated viruses containing the gene that encodes ACE2. This invention allows to administer angiotensin-(1-9) or derivatives thereof via oral route, injections, pump continuous infusion, or elevate its levels in the organism through treatment with angiotensin I-converting enzyme inhibitors, angiotensin II receptor antagonists (ARA II), with Rho kinase inhibitors, with L-calcium channel antagonists, and/or with diuretics. | 07-05-2012 |
| 20120220524 | ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES - The present invention describes methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. An increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression. | 08-30-2012 |
| 20120322733 | NOVEL PEPTIDYL ALPHA-HYDROXYGLYCINE ALPHA-AMIDATING LYASES - The present patent application concerns an enzyme capable of catalysing the conversion of a α-hydroxyglycine to an α-amide and the use of such enzymes for producing a C-terminal α-amidated peptide. | 12-20-2012 |
| 20120329713 | METHOD FOR DETERMINING LIKELIHOOD OF CLINICAL RECURRENCE OR CLINICALLY STABLE DISEASE OF PROSTATE CANCER AFTER RADICAL PROSTATECTOMY - This invention describes compositions and methods for use in PSA assays having low functional sensitivity which are useful, for example, in the detection of early stage recurrence of prostate disease following treatment and in the determination of whether patients have early stage biochemical reoccurrence (ES-BCR) or stable disease. | 12-27-2012 |
| 20130005654 | THERAPEUTIC AGENT FOR ACCELERATING RECOVERY OF ANIMAL UNDER MEDICAL TREATMENT - An object of the present invention is to provide a therapeutic agent for accelerating recovery to accelerate a return to normal physical conditions by administering to an animal not in good health and under medical treatment, a treatment method, and the like. There is provided a therapeutic agent for accelerating recovery for animal use to accelerate the improvement of a physical condition of an animal under medical treatment which has a decreased activity (vigor) and is exhausted, which contains ghrelin or a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient and improves one or more of evaluation parameters consisting of activity (vigor), blood cell test values, biochemical test values, body temperature, the degree of anger or anxiety, and respiratory rate. | 01-03-2013 |
| 20130005655 | COMBINATION THERAPY USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP - A composition comprising doxepin, or a pharmaceutically acceptable salt, or prodrug thereof, and a compound that enhances sleep onset, sleep maintenance or reduces early morning awakenings. These compositions are useful for treating multiple manifestations of insomnia. | 01-03-2013 |
| 20130029910 | METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST - The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist. | 01-31-2013 |
| 20130085104 | THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 04-04-2013 |
| 20130123177 | METHOD OF TREATING BRAIN INJURY - A novel use of a neuropeptide for treating brain injury in a subject in need thereof is provided. The present invention also provides various amenable routes of administering urocortin, that is, via injection intracerebroventricularly and intraperitoneally, and via intravenous bolus administration. | 05-16-2013 |
| 20130137635 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE - This invention relates to tryptophan hydroxylase inhibitors, compositions comprising them, and methods of their use for the treatment, management and/or prevention of metastatic bone disease. | 05-30-2013 |
| 20130143814 | Protein Therapy for Treatment of Eye Diseases - The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein. | 06-06-2013 |
| 20130157950 | METHOD FOR TREATING AND/OR PREVENTING NEURODEGENERATIVE DISEASE BY ADIPONECTIN RECEPTOR AGONIST - The present invention was accomplished for the purpose of developing a method for effectively treating and/or preventing synucleinopathies, and is based on a discovery that an adiponectin receptor agonist suppresses α (alpha)-synuclein aggregation, tau phosphorylation and a decrease in proteasomal activity. | 06-20-2013 |
| 20130184213 | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders - Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders. | 07-18-2013 |
| 20130190237 | METHODS FOR CATEGORISING CANCER SUCH AS BREAST CANCER - A method for aiding in categorising or determining prognosis in a patient with cancer, for example breast cancer (or, for example, hepatocellular, bladder or gastric cancer) or in selecting a therapeutic strategy for a patient with cancer, for example breast cancer (or, for example, hepatocellular, bladder or gastric cancer), the method comprising the step of assessing the level of LMTK3 nucleic acid, protein or activity in a sample obtained from the patient and/or assessing the patient's genotype for LMTK3, optionally at position rs8108419 (in intron 2 of the LMTK3 gene) and/or position rs9989661 (in intron 15 of the LMTK3 gene). The method may further comprise the step of assessing the level of ERa nucleic acid, protein or activity in a sample obtained from the patient, particularly in the case of breast cancer. If the level of LMTK3 nucleic acid, protein or activity in the sample is an elevated level and/or the genotype is LMTK3 rs8108419AA or LMTK3 rs9989661 CT or CC then the selected treatment regime may be an aggressive treatment regime or may comprise treating the patient with an inhibitor of LMTK3 activity and/or an inhibitor of Fox03a activity. If the level of LMTK3 nucleic acid, protein or activity in the sample is not elevated and/or the genotype is LMTK3 rs8108419GA or GG or LMTK3 rs9989661 TT then the selected treatment regime may be a less aggressive treatment regime. | 07-25-2013 |
| 20130196912 | BETA THYMOSIN FRAGMENTS - Peptide fragments having amino acid sequences corresponding to portions of a thymosin beta 4, a thymosin beta 10 and/or a thymosin beta 15 amino acid sequence are provided, as well as methods of treatment utilizing same. | 08-01-2013 |
| 20130196913 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 08-01-2013 |
| 20130203669 | MEDICAMENT - Analysis of a goat serum product with many therapeutic effects is described. The product is identified as containing proopiomelanocortin (POMC) and Corticotropin releasing factor (CRF) peptides, as well as breakdown products of these peptides. We describe methods of treatment of diseases including cancers, multiple sclerosis, and neural disorders using these peptides and their products, as well as medicaments including such peptides and methods of producing the peptides. | 08-08-2013 |
| 20130210726 | COMPOSITIONS AND METHODS FOR TREATMENT OF PERIPHERAL VASCULAR DISEASE - The present invention relates to compositions and methods for the treatment of peripheral vascular disease (PVD). In particular, the invention provides compositions and methods for treatment of critical limb ischemia, and related diseases, disorders or conditions, based on the use of angiotensin-(1-7) peptides or functional equivalents, analogs or derivatives, angiotensin-(1-7) receptor agonists, ACE2 and/or ACE2 activators. | 08-15-2013 |
| 20130217626 | Novel Bioactive Protein Isolated From Chinese Yam and Uses Thereof - A protein isolated from the Chinese yam | 08-22-2013 |
| 20130217627 | THERAPEUTIC APPLICATION OF ADIPONECTIN IN PATIENTS WITH VENTRICULAR FIBRILLATION - A therapeutic method for cardiac diseases such as angina, myocardial infarction, arrhythmia (ventricular tachycardia, ventricular fibrillation and atrial fibrillation) is provided. The method is characterized by intracoronary administration of adiponection to mammals. | 08-22-2013 |
| 20130237478 | COMPOSITIONS AND METHODS FOR TREATMENT OF PERIPHERAL VASCULAR DISEASE - The present invention relates to compositions and methods for the treatment of peripheral vascular disease (PVD). In particular, the invention provides compositions and methods for treatment of critical limb ischemia, and related diseases, disorders or conditions, based on the use of angiotensin-(1-7) peptides or functional equivalents, analogs or derivatives, angiotensin-(1-7) receptor agonists, ACE2 and/or ACE2 activators. | 09-12-2013 |
| 20130252889 | COMPOSITION COMPRISING VLP AND AMYLOID BETA PEPTIDE - The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the AD-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia. in particular dementia of the A | 09-26-2013 |
| 20130274191 | METHODS AND COMPOSITIONS FOR THERAPEUTIC MODULATION OF ALDOSTERONE LEVELS IN HEART DISEASE - The disclosure describes the contribution of elevated levels of circulating alsosterone to heart disease and other hyperaldosteronic conditions. Since activation of beta-arrestin I (beta.arr-1) by the Angiotensin II (AngII) type 1 receptor (AT1R) mediates AngII-induced aldosterone production, beta-arrestin I (beta.arr-1) is a therapeutic target for heart disease. Specifically, the disclosure provides a beta.arr-1 protein fragment comprising the C-terminus of beta.arr-1 (beta.arr1ct; SEQ ID NO:3), compositions containing this protein fragment, and methods of using this protein fragment to reduce elevated levels of aldosterone in heart disease and other hyperaldosteronic conditions by inhibition of beta-arrestin (beta.arr-1). These compositions and methods are of therapeutic benefit in chronic heart failure and progression to heart failure after myocardial infarction (MI). Additionally, the invention provides an AngII peptide analog (SEQ ID NO:4), compositions containing this analog, and methods of using this analog for stimulation of beta.arr-1 activity and aldosterone production. | 10-17-2013 |
| 20130296240 | PNEUMONIA BIOMARKERS - Ghrelin signal peptide fragment assays and kits useful in the diagnosis, prognosis, risk stratification, assessing, staging, monitoring, categorizing and determination of further diagnoses and treatment regimens in subjects with various disorders, diseases and conditions including, pneumonia, heart failure, or pneumonia and heart failure or suspected pneumonia, heart failure, or pneumonia and heart failure, and methods for monitoring treatment. | 11-07-2013 |
| 20130303450 | USE OF SOMATOSTATIN ANALOGS IN MENINGIOMA - The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of meningioma. | 11-14-2013 |
| 20130303451 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING SAME - A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed. | 11-14-2013 |
| 20130345133 | Adiponectin for Treating Pulmonary Disease - The present invention provides an agent for inhibiting alveolar airspace enlargement containing adiponectin or an agent for inhibiting alveolar wall destruction containing adiponectin. The pulmonary disease therapeutic agents of the present invention are highly safe drugs that possess an excellent effect of decreasing the deterioration of the pulmonary function, such as airflow limitation, and exhibit an extremely high effect of treating pulmonary disease accompanied by irreversible deterioration in pulmonary function, with fewer adverse side effects such as nausea, vomiting and gastric acid secretion. | 12-26-2013 |
| 20140024587 | COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS - A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. | 01-23-2014 |
| 20140024588 | METHOD FOR INDUCING SUSTAINED IMMUNE RESPONSE - A method for promoting a sustained increased level of T-cell production in immunocompromised subjects in which method enkephalin peptides are administered according to an intermittent dose schedule. In particular, the method involves treatment of immunocompromised patients which includes the administration of enkephalin, either alone or in conjunction with other therapies, in an initial dosage regimen, with periodic booster dosages of enkephalin as necessary to maintain sustained immune system response. | 01-23-2014 |
| 20140031286 | Angiotensin (1-7) Dosage Forms and Uses Thereof - The present invention provides angiotensin (1-7) pharmaceutical compositions, dosage forms, and methods for their use, and methods for treating or limiting development of acquired immune deficiency syndrome. | 01-30-2014 |
| 20140113862 | METHOD FOR SITE-SPECIFIC POLYVALENT DISPLAY ON POLYMERS - The present invention relates to novel complex peptidomimetic products comprising multiple homogeneous or heterogeneous pendant groups that are site-specifically positioned along a linear oligomer or polymer scaffold and methods of making thereof. More specifically, the invention relates to N-substituted glycine peptoid oligomers or peptoids and their use as substrates for azide-alkyne [3+2]-cycloaddition conjugation reactions and subsequent additional rounds of oligomerization and cycloaddition. The methods of the invention may also be used to generate peptoid-peptide hybrid or peptide products comprising multiple homogeneous or heterogeneous pendant groups, which are positioned precisely along the linear oligomer or polymer scaffold. | 04-24-2014 |
| 20140135266 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FIBROSIS - A pharmaceutical composition for preventing fibrosis, treating fibrosis, and/or preventing the progression of fibrosis contains stanniocalcin 1 (STC1) as an active ingredient; or a pharmaceutical composition for preventing pulmonary fibrosis, treating pulmonary fibrosis, and/or preventing the progression of pulmonary fibrosis contains STC1 as an active ingredient. A method for treating, preventing or suppressing progression of fibrosis using the above pharmaceutical composition. The fibrosis may be pulmonary fibrosis. | 05-15-2014 |
| 20140148389 | METHODS FOR ACCELERATING WOUND HEALING BY ADMINISTRATION OF ADIPOKINES - The present disclosure provides a method, composition and kit for treatment of inflammatory disease and disorder using PKC isoform modulators. | 05-29-2014 |
| 20140296143 | Angiotensin-(1-7) As A Chemoprevention Agent - Disclosed is the use of angiotensin-(1-7) peptide as an anti-cancer and chemoprevention therapeutic. Embodiments of the present invention comprise methods and compositions to prevent cancer or to reduce the risk of cancer in an individual comprising administering to the individual a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor to inhibit at least one of formation of a tumor (tumorigenesis), the proliferation of tumor cells, the growth of tumor cells, or metastasis of tumor cells in the individual. Cancers treated using the methods and compositions described herein may include cancers having an angiotensin-(1-7) receptor, including, but not limited to, breast cancer, colon cancer, glioblastoma, and lung cancer. | 10-02-2014 |
| 20140303082 | SELECTIVE GPCR LIGANDS - In the past decade a great deal of structural information for class A-GPCRs (G protein-coupled receptors) has emerged. However, the structural and electronic basis of ligand selectivity for closely related receptor subtypes such as the angiotensin receptors AT1aR and AT2R, which present completely diverse biological functions in response to the same ligand, is poorly understood. In order to monitor complex responses in biosystems it is useful to have ligands that present a gradient in terms of selectivity. In this study we present an efficient method to tune ligand selectivity for the two angiotensin II receptor subtypes, AT1aR and AT2R, by controlling aromatic-prolyl interactions in angiotensin II, through alternation of aromatic electronics. On the basis of this strategy, an AT2R selective and high affinity agonist analogue (Ki=3 nM) was obtained. | 10-09-2014 |
| 20140315808 | INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM FOR THE TREATMENT OF RENAL, VASCULAR AND CARTILAGE PATHOLOGY - A method of treating a disease or condition in which up-regulating GAGs is therapeutically beneficial is disclosed. The method comprises locally administering to a subject a therapeutically effective amount of an agent capable of down-regulating activity or expression of a component of the renin-angiotensin system. | 10-23-2014 |
| 20140329747 | Compositions and Methods for Treating Renal Failure - The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis. | 11-06-2014 |
| 20140371146 | Glycoprotein Hormone Long-Acting Superagonists - This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity. | 12-18-2014 |
| 20150051150 | COMPOSITIONS, METHODS AND ASSAYS COMPRISING AMYLIN OR AMLYIN ANALOGS FOR ABETA-PEPTIDE MEDIATED DISORDERS - Provided herein are methods of reducing and/or inhibiting A deposition or A plaque formation in the brain, and/or inhibiting or slowing the progression of disorders mediated by A deposition or A plaque formation using therapeutically effective amounts of amylin agonist compounds or pharmaceutical compositions comprising amylin agonist compounds. As demonstrated herein, amylin and amylin analog administration improves cognition, including memory. Also provided herein are non-invasive, inexpensive amylin or amylin analog challenge assays and methods and kits thereof for detecting the presence of plaques comprising A? peptide in the brain, and for identifying individuals at increased risk for Alzheimer's disease (AD) and/or amnestic mild cognitive impairment. | 02-19-2015 |
| 20150072932 | POLYPEPTIDES AS APELIN INHIBITORS AND USES THEREOF - The present invention relates to polypeptides and their uses as apelin inhibitors. More particularly, the present invention relates to a polypeptide comprising the sequence as set forth in SEQ ID NO:1 wherein at least one arginine residue at position 18, 19, 22 or 23 has been substituted or deleted. | 03-12-2015 |
| 20150099702 | USE OF RNA INTERFEARENCE, FARNESOIC ACID AND RECOMBINANT PROTEIN APPROACH TO INDUCE GONAD MATURATION IN CRUSTACEAN SPECIES - This invention is directed to the compositions and methods for inducing female gonad maturation in crustacean species such as shrimp, lobster or crab. In one embodiment, the composition for inducing gonad maturation comprises a dsRNA corresponding to the GIH DNA, recombinant protein of a gonad stimulatory hormone (GSH) and farnesoic acid (FA). In another embodiment, the composition for inducing gonad maturation comprises a dsRNA corresponding to the GIH DNA, recombinant MeMIH-B protein and farnesoic acid (FA). | 04-09-2015 |
| 20150111823 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE - The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin. | 04-23-2015 |
| 20150111824 | Pharmaceutical Formulations Comprising Incretin Mimetic Peptide and Aprotic Polar Solvent - The present disclosure is directed to stable pharmaceutical formulations and uses thereof. | 04-23-2015 |
| 20150141336 | Pancreatic Peptide Compounds and Use - The invention relates to novel use of Pancreatic Polypeptides as well as novel Pancreatic Polypeptides and compositions thereof. Such peptides can be used in treating or preventing conditions responsive to Y4 and/or Y5 receptor activation, such as cachexia. | 05-21-2015 |
| 20150141337 | MANUFACTURE OF DEGARELIX - The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance. | 05-21-2015 |
| 20150290293 | METHODS FOR CHRONIC PAIN MANAGEMENT AND TREATMENT USING HCG - A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonadotropin (uHCG and/or rHCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide an amount therapeutically bioequivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A combination product is also described, which includes a supply of the HCG-related drug, a delivery device, and a conversion scale for therapeutic bioequivalence that identifies the specific amount and route of administration for chronic pain or central sensitization as an indication of the drug. | 10-15-2015 |
| 20150293114 | DIAGNOSIS AND TREATMENT OF ENDOMETRIOSIS AND RELATED CONDITIONS - The technology described herein relates to KIM-1 and the diagnosis, prognosis, and treatment of endometrial diseases and disorders. | 10-15-2015 |
| 20150313829 | TOPICAL FORMULATIONS FOR THE PREVENTION AND TREATMENT OF ALOPECIA AND INHIBITION OF HAIR GROWTH - The present invention discloses formulations for the treatment and prevention of alopecia; the formulations comprise angiotensin-(1-7) and/or their analogues, encapsulated in ultradeformable vesicles prepared from specific combinations of phospholipids and surfactants, which confer efficacy to topical application in the control of hair growth, which indicates their great potential for the prevention and treatment of alopecia. The invention also describes formulations containing A779 Mas receptor antagonist of angiotensin-(1-7) and/or their analogues and their use in inhibiting hair growth. | 11-05-2015 |
| 20150329912 | BIOMARKERS IN CANCER, METHODS, AND SYSTEMS RELATED THERETO - This disclosure relates biomarkers of cancer, e.g. prostate cancer. The biomarkers may be altered expression of nucleic acids, mutations, or proteins encoded therefrom. In certain embodiments, the disclosure relates to methods for diagnosing pro-state cancer, methods of distinguishing between less aggressive and high aggressive prostate cancer, methods of determining predisposition to recurrence of prostate cancer, methods of monitoring progression/regression of prostate cancer, methods of assessing efficacy of compositions for treating prostate cancer, and methods of screening compositions for activity in modulating biomarkers of prostate cancer. | 11-19-2015 |
| 20150369815 | METHOD FOR DETECTING THE PRESENCE OF A GYNAECOLOGICAL GROWTH - The invention relates to a method for detecting the presence of a gynaecological growth, in particular for the diagnosis of endometriosis. The invention also relates to a method of identifying a biomarker for detecting the presence of a gynaecological growth and to biomarkers identified by said method. | 12-24-2015 |
| 20150369820 | NOVEL DISEASE-MARKER - The invention relates to the use of soluble CD206 as a general health/disease marker, and a specific marker for liver disorders, sepsis, and pneumonia. | 12-24-2015 |
| 20150374791 | PROTEIN THERAPY FOR TREATMENT OF RETINAL DISEASES - The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein. | 12-31-2015 |
| 20160000880 | Methods for Treating Multiple Sclerosis - The present invention provides methods for treating or limiting development of multiple sclerosis by administering angiotensin peptides to a subject with multiple sclerosis or at risk of developing multiple sclerosis. | 01-07-2016 |
| 20160045571 | OSTEOCALCIN AS A TREATMENT FOR COGNITIVE DISORDERS - Methods and compositions for treating or preventing cognitive disorders in mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-1B signaling pathway involving gamma-carboxylase and osteocalcin, e.g., by administration of undercarboxylated/uncarboxylated osteocalcin. Disorders amenable to treatment by the methods include, but are not limited to, cognitive loss due to neurodegeneration associated with aging, anxiety, depression, memory loss, learning difficulties, and cognitive disorders associated with food deprivation during pregnancy. | 02-18-2016 |
| 20160051622 | Accelerated healing of eye injuries by angiotensin peptides - Disclosed herein are methods for treating eye injuries by administering one or more angiotensin peptides to a subject with an eye injury. | 02-25-2016 |
| 20160051630 | POSTPRANDIAL GASTROKINETIC AGENT - To provide a therapeutic agent for gastrointestinal disorder such as diabetic gastroparesis. A postprandial gastrokinetic agent containing (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients, in which both the ingredients (A) and (B) are administered so as to act on the stomach after food intake. | 02-25-2016 |
| 20160082080 | HUMANIN, ANALOGS AND CANCER TREATMENT METHODS AND USES THEREOF - Described herein are methods of enhancing chemotherapeutic treatment of a hyperproliferative disorder by, in part, administering a composition comprising one or more humanin polypeptides to a subject receiving chemotherapy. | 03-24-2016 |
| 20160083713 | NOVEL PEPTIDYL ALPHA-HYDROXYGLYCINE ALPHA-AMIDATING LYASES - The present patent application concerns an enzyme capable of catalysing the conversion of a α-hydroxyglycine to an α-amide and the use of such enzymes for producing a C-terminal α-amidated peptide. | 03-24-2016 |
| 20160129072 | ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION - The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less. | 05-12-2016 |
| 20160144049 | CARRIERS FOR IMPROVED DRUG DELIVERY - The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties. | 05-26-2016 |
| 20160151458 | Use Of Unacylated Ghrelin, Fragments And Analogs Thereof As Antioxidant | 06-02-2016 |
| 20160199350 | COMBINATION OF HDAC INHIBITORS WITH THROMBOCYTOPENIA DRUGS | 07-14-2016 |
| 20160199352 | PYRAZOLOANTHRONE AND DERIVATIVES THEREOF FOR TREATMENT OF CANCERS EXPRESSING MISSRII | 07-14-2016 |
| 20160199436 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | 07-14-2016 |
| 20220135638 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF - The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P | 05-05-2022 |
